DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd has a price-to-earnings (PE) ratio of 2102.0 in the Healthcare Services sector.

What is the market capitalisation of Aspira Pathlab & Diagnostics Ltd?

Aspira Pathlab & Diagnostics Ltd has a market capitalisation of approximately ₹110 crore.

Aspira Pathlab & Diagnostics Ltd

ASPIRAPATHLABLTD·NSE·Healthcare Services

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare Services · Healthcare Service Provider

A steady, established business

52W₹49

₹136-56%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹110 Cr

P/E Ratio

2102.00Expensive

P/B Ratio

8.84

EPS

₹2.01

Book Value

₹11.88

ROE

0.51%Weak

ROCE

17.37%Decent

Dividend Yield

0.00%

Debt / Equity

0.27Low

Face Value

₹10.00

52W High

₹135.88

52W Low

₹49.00

Sector

Healthcare Services

Industry

Healthcare Service Provider

Expensive

Narrow moatHigh uncertainty

Fair value estimate

₹15

No recent traded price

BearFair valueBull

₹13₹15₹17

/100

Business quality — Watch the fundamentals

Growth 50Profitability 21Efficiency 47Valuation 43

Plain English

Our view

A steady, established business
Low debt relative to equity
Weak returns on equity (1%)

Strengths

Low debt relative to equity

Risks

Weak returns on equity (1%)
Expensive — trades at 2102× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

2102.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

0.5%Weak

Above 15% is considered healthy for Indian equities

ROCE

17.4%Decent

Above 18% means capital is working hard

Debt/Eq

0.27Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹110 Cr

P/B

8.84

EPS

₹2.01

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 2102.0×

Growth

Strong

+16% rev CAGR

Profitability

Modest

0.5% ROE

Financial health

Rock solid

D/E 0.27

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.7%

+8.1%

10Y

—

Profit

—

+7.7%

10Y

+52.2%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Debtor days have improved from 42.1 to 25.3 days.

Watch-outs

Cons

Stock is trading at 8.40 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
Promoter holding is low: 18.4%
Company has a low return on equity of -2.31% over last 3 years.
Company might be capitalizing the interest cost
Earnings include an other income of Rs.0.52 Cr.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

18%

Promoter

Promoters

18.4%0.00

Public

60.1%-0.01

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

21.6%

Total shareholders

1,769-15 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter18.39%

Public60.06%

Others21.55%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]